Clinical Trial Update: BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study) [Phase 2]

View source ↗

Summary

A Phase 2 BEAR study investigating BI-754091 in combination with Afatinib for refractory esophageal squamous cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• BI-754091
• Gilotrif (Afatinib)

Snippet

Sponsor: National Health Research Institutes, Taiwan | Conditions: Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Status: COMPLETED